| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Brain Mets:
NCCTG-#N-0574: PHASE III RANDOMIZED TRIAL OF THE ROLE OF WHOLE BRAIN RADIATION THERAPY IN ADDITION TO RADIOSURGERY IN PATIENTS WITH ONE TO THREE CEREBRAL METASTASES
(1_20061103_118)
Participants will be randomized to one of two arms. Under Arm A, participants will go on for Radiosurgery (SRS); and under Arm B, participants will received Radiosurgery (SRS) plus Whole Brain Radiation (WBRT). This is then followed by an observation period until withdrawal or refusal to be on the study.
- Brain Tumor in Children -
COG #ACNS0332 EFFICACY OF CARBOPLATIN ADMINISTERED CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN OTHER THAN AVERAGE RISK MEDULLOBLASTOMA/PNET PATIENTS
(1_20090106_118)
This is a randomized, open-label, factorial-designed, multicenter study. Patients are randomized according to location of disease and status. Patients are placed on 1 of 4 treatment arms. Arm I will receive standard chemoradiotherapy along with standard maintenance therapy. Arm II will receive standard chemoradiotherapy, plus carboplatin and standard maintenance therapy. Arm III will receive standard chemoradiotherapy, standard maintenance therapy, plus isotretinoin, and continuation therapy with isotretinoin. And, Arm IV will receive standard chemoradiotherapy plus carboplatin, standard maintenance therapy plus isotretinoin, and continuation therapy with isotretinoin. After completion of study treatment, patients are followed periodically for up to 10 years. A total of 300 patients will be accrued for this study.
- Brain Tumor in Children -
COG #ANBL0032: PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (CH14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
(1_20080603_118)
There are two arms to this study. Participants will be randomized to one of the two arms. Arm A will be given orally isotretinoin; and Arm B will receive orally isotretinoin and immunotherapy. Prior to start of study drug, participants may undergo radiation therapy, tumor evaluation, bone marrow biopsy and additional radiographical studies. In rare cases where there is persistent tumor, a tumor biopsy may be required.
- Brain Tumor in Children -
COG #ANBL0531: RESPONSE-AND BIOLOGY-BASED THERAPY FOR INTERMEDIATE-RISK NEUROBLASTOMA
(2_20081107_118)
Enrollment in this study requires enrollment in ANBL00B1. All participants with the exception of patients with INSS 4S disease will have an operation to remove as much of the primary tumor and involved lymph nodes as can be done safely. If the participant is found to be at intermediate risk, those participants are enrolled on ANBL0531 and split into Group 2, Group 3 and Group 4. These groups are determined by using clinical and biologic information such as age, INSS stage, MYCN status, INPC histopathology classification, and tumor DNA index. Each group will receive a pre-determined number of cycles and drug combinations. If after enrollment on ANBL00B1 the participant is found not to be eligible for ANBL0531, they may be offered other applicable study participation.
- Lymphoma of Central Nervous System -
ECOG #E1F05: PHASE II STUDY OF RITUXIMAB GIVEN IN CONJUNCTION WITH STANDARD CHEMOTHERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA
(2_20070216_118)
This study is using all FDA approved drugs; Rituzimab, Methotrexate, Leucovorin, Vincristine, Procarbazine, Ara-C and Dexamethasone. All of these drugs are commercially available, however, the dose and the way the drug is given is different in this study. Some of the drugs will be given by IV infusion and others orally. The study will last 10 weeks, followed by a follow-up visit and end of treatment assessment. Participants will need to keep a pill diary at home.
- Study Closed to Accrual:
Brain Tumor, Recurrent in Adults -
NCCTG #N0572: A PHASE I/II TRIAL OF SORAFENIB AND CCI-799 IN PATIENTS WITH RECURRENT GLIOBLASTOMA
(2_20081001_118)
Participants will be assigned to one of two groups. Participants in Group 1 will undergo surgery and receive oral sorafenib 2 times a day on days 1-8, and receive temsirolimus IV on day 1. Participants will undergo surgery on day 8 and after recovering from surgery will receive sorafenib and temsirolimus as in Phase I which will be a dose escalation study of temsirolimus and oral sorafenib 2 times a day on days 1-28 and temsirolimus by IV over a 30 minute period on days 1, 8, 15 and 22. This treatment will repeat every 28 days in the absence of disease progression or until unacceptable toxicity. Group 2 participants’ not undergoing surgery will receive sorafenib and temsirolimus as in Phase I listed above.
- Study Closed to Accrual: Brain Tumor in Children -COG #ANBL0032: PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (CH14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
(1_20080603_118)
There are two arms to this study. Participants will be randomized to one of the two arms. Arm A will be given orally isotretinoin; and Arm B will receive orally isotretinoin and immunotherapy. Prior to start of study drug, participants may undergo radiation therapy, tumor evaluation, bone marrow biopsy and additional radiographical studies. In rare cases where there is persistent tumor, a tumor biopsy may be required.
|
|
